N. Burkhardt, B. Strober, A. Brnabic, A. Schacht,
IXE (anti-interleukin-17A monoclonal antibody with a high binding afﬁnity) is a new treatment for moderate-to-severe psoriasis. We compared efﬁcacy/quality-of-life (QoL) data indirectly between IXE and SEC (anti-interleukin-17A monoclonal antibody) clinical trials using MAIC. The inclusion/ exclusion criteria in one SEC trial were applied to IXE trials. IXE patient data were re-weighted to balance the aggregate data regarding selected baseline characteristic means. We used the Bucher method (BU) and two modiﬁed Signorovitch methods (SG) to compare IXE 80 mg every 2 weeks (IXEQ2W) to SEC 300 mg/week via the common comparator (bridge), etanercept, with respect to efﬁcacy (Psoriasis Area Severity Index [PASI]) and QoL (Dermatology Life Quality Index [DLQI]) over the ﬁrst 12 weeks. PASI90 response rates (RRs) for IXEQ2W were 15.1% (p < 0.001), 13.7% (p = 0.003), and 13.4% (p = 0.005) higher than SEC using the BU, SG total, and SG separate arms methods. PASI100 RRs were signiﬁcantly higher for IXEQ2W vs. SEC with response differences (RDs) of 14%, 15.2%, and 15% for the three approaches. For PASI75, the RRs were high for both treatments, and IXE was only significantly better using BU (RD = 8.6%, p = 0.044), but not for the SG approaches (RD = 4.3%, p = 0.368; RD = 4%, p = 0.399). For DLQI(0,1), RRs for IXE2QW relative to SEC (differences of 4.1%, 0.6%, and 0.3%) were comparable. Both treatments achieved high RRs for PASI75, with small differences when adjusting for baseline differences. For PASI90 and PASI100, RRs differed signiﬁcantly, favoring IXE over SEC. Efﬁcacy gains did not translate into signiﬁcant differences in QoL as measured by DLQI(0,1) at Week 12.